CTi Biopharma — Cell Therapeutics — Investor Presentation (November 2011)
23 slides from CTi Biopharma's investor presentation, Nov 7, 2011
Slide 1: Cell Therapeutics, Inc.
Cell Therapeutics, Inc. James A. Bianco, M.D. CEO Exhibit 99.1
Slide 2: Forward Looking Statement
Forward Looking Statement The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risks associated with preclinical, clinical and sales and marketing developments in the biopharmaceutical industry in general and in
Slide 3: Important Advances in Treating Cancer
Important Advances in Treating Cancer 3 novel “late stage” cancer drug candidates Pixantrone – marketing authorizations filed; potential approval Opaxio – completing final stage (III) clinical testing Tosedostat – entering final stage (III) clinical testing Large market opportunities addressing unme
Slide 4: Innovative & Established Cancer Drug Pipeline
Innovative & Established Cancer Drug Pipeline Under Review > Third-line r/r aggressive NHL (PIX301) > Second-line r/r aggressive NHL (PIX306) First-line aggressive NHL (PIX203) Second-line metastatic breast cancer (NCCTG) First-line Ovarian cancer First-line GBM cancer + XRT Elderly high-risk r/r AM
Slide 5: Anthracyclines
Anthracyclines “Cornerstone” potentially curative therapy 1 st line therapy Breast cancer / acute leukemia / NHL However all anthracyclines cause cumulative, irreversible damage to heart muscle Patients limited to life time maximum dose 450mg/m 2* * Swain et al, chest XRT or cyclophosmaide Incidence
Slide 6: Pixuvri (pixantrone) Product Advantages
Pixuvri™ (pixantrone) Product Advantages More potent DNA alkylator than doxorubicin Lacks structural motifs that lead to cardiac toxicity Significant reductions in biochemical, echo-cardiographic and severe clinical symptoms (CHF) Vs doxorubicin O O O O H O H O H O O H O O O H N H H N O O N H N H N
Slide 7: Pixuvri (pixantrone): Overview
Pixuvri™ (pixantrone): Overview Pivotal (PIX301)Trial Significant increase in Complete and Overall Response rates compared to standard chemotherapy Significant (40%) decrease in risk of dying or progression of disease over 2 years Well tolerated, most common side effect – low white cell counts Marke
Slide 8: Novartis Pixantrone Option
Novartis Pixantrone Option NVS has option to negotiate a license to pixantrone Potentially up to $104 million in registration/sales milestones $17.5mm on approval for r/r aNHL 28% to 32% royalty on US net sales NVS assumes certain costs and pays CTI to field 35 sales people CTI not obligated to lice
Slide 9: US Patients/year Treated with Anthracyclines
US Patients/year Treated with Anthracyclines Pixuvri™ Phase II NDA/MAA o Development program to enhance commercial potential post approval o Competitive advantages o Potential to become standard of care Source: Tandem Cancer Audit 2004
Slide 10: Tosedostat: Overview
Tosedostat: Overview New drug class: tumor selective targeted agent Works by depriving cancer cells building blocks needed to make proteins essential for their survival Oral, once daily dosing, well tolerated Encouraging data in elderly r/r AML (Acute Myeloid Leukemia) and r/r MDS (Myelodysplasia or
Slide 11: Phase I/II Clinical Study of Tosedostat in AML and Myelodysplasia
Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia Bob Lowenberg, Gareth Morgan, Gert J. Ossenkoppele, Alan K. Burnett, Pierre Zachée, Ulrich Dahrsen, Daan Dierickx, Carsten Muller-Tidow, Pieter Sormeveld, Utz Krug, Hl
Slide 12: Unmet Medical Need in MDS and AML
Unmet Medical Need in MDS and AML AML and MDS are common diseases MDS often progresses to AML Is a disease of elderly 70% of patients are over age 60 The majority of elderly patients with MDS and AML do not tolerate standard intensive chemotherapy 35% will die from side effects of standard intensive
Slide 13: Tosedostat: OPAL Interim Study Results
Tosedostat: OPAL Interim Study Results Phase II- r/r elderly AML (n=75 patients) Oral once-a-day dosing for 6 months Encouraging interim data presented at ASCO 15 of 50 (30%) evaluable patients had bone marrow response; - 6 (12%) of which were complete bone marrow responses 9 of 23 (39%) patients wh
Slide 14: Tosedostat Summary Deal Terms & Structure
Tosedostat Summary Deal Terms & Structure Exclusive co-development and marketing rights in the Americas from Chroma Therapeutics, Ltd Cost-sharing CTI bears 75% of all development costs Registration trials aimed at US/EU regulatory approval Initial Payments $5mm upon execution $5mm upon initiation o
Slide 15: US Market Size: Selective Blood Related Cancers
US Market Size: Selective Blood Related Cancers Relapsed or refractory MDS (IPSS>2) Currently no approved drugs Existing therapies come off patent in 2011, and 2013 18,000 patients/year Relapsed or refractory elderly AML Currently no approved drugs 18,300 patients/year Other potential indications (p
Slide 16: Tosedostat Market Opportunity: Current targeted agents
Indication WW 2010 sales* Patent expiration Tosedostat Market Opportunity: Current targeted agents MDS $200MM MDS $534MM Multiple Myeloma/ Mantle Cell $1.5B Multiple Myeloma MDS Deletion 5q $2.5B VELCADE *Information from SEC filings.
Slide 17: A bioengineered version of Taxol (paclitaxel)
A bioengineered version of Taxol® (paclitaxel) Singer et al. In: Adv Exp Med Biol . 2003; 519:81-99
Slide 18: Opaxio vs Taxol
A bioengineered version of Taxol® (paclitaxel) Taxol® (paclitaxel) 3hr to 24 hr infusion, pre-medications required Opaxio™ 15-20 minute infusion, NO pre-medications required
Slide 19: Opaxio: Ovarian Cancer Pivotal Trial (GOG212)
Opaxio™ 95% of women with advanced Ovarian Cancer achieve CR with standard (taxol/platinum) chemotherapy Half (median) will relapse within 8 months, and die in 44 months Ovarian Cancer Pivotal trial (GOG212) Can monthly OPAXIO for 12 months prolong time to progression and improve survival in women w
Slide 20: Opaxio: Radiation Sensitizer and Brain Tumors
Opaxio™ Potential registration route as radiation sensitizer Tumor selective, 8-12X increase in radiation sensitization vs Taxol (0.8x increase) Malignant Brain Tumor Study (n=25 patients ) Opaxio added to standard therapy (TMZ+XRT) Compared to landmark trial* - Median PFS 13.5 months vs. 6.9 months
Slide 21: US Patients/year Treated with Taxanes
US Patients/year Treated with Taxanes Source: Tandem Cancer Audit 2004 NSC Lung Breast Ovarian H&N Prostate 92,400 81,600 27,200 13,600 13,600
Slide 22: Capital Structure/Financials
Capital Structure/Financials Dual Listed NASDAQ:CTIC, MTA:CTIC.MI Shares outstanding ~193 million Only $11mm convertible senior notes outstanding Due December 2011 Only common shares outstanding Manageable burn rate Cash end of Q3-2011 ~$45.2 million Excludes :~$8.2 million from settlement agreement
Slide 23: 2012 Potential News Flow & Key Milestones
2012 Potential News Flow & Key Milestones Pixantrone CHMP opinion on MAA and potential approval FDA review of NDA and potential approval Novartis decision on pixantrone option Tosedostat Final OPAL data to be highlighted at ASH Start of Tosedostat phase III r/r MDS trial Opaxio OPAXIO phase III ovar
Cell Therapeutics — Investor Presentation (November 2011) on 6ix